We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising.
Read our
Privacy Policy
CAR-T Cell Therapy Development Service for Multiple Myeloma (MM)
In the formulation of a CAR-T cell therapy development plan for multiple myeloma, our company engages in in-depth communication with customers. Our services encompass the entire drug development process, from discovery to IND application, including target discovery & validation, CAR-T cell construct design & screening, in vitro & in vivo evaluation.
At our company, we provide a complete range of preclinical services specifically designed to propel rare disease research and drug development forward. Our all-inclusive, one-stop preclinical platform delivers comprehensive solutions, encompassing everything from disease modeling and diagnostic development to therapeutic evaluation, all within one integrated system.
Protheragen’s innovative Skin-on-a-Chip model replicates the physiological and pathological features of human skin using advanced microfluidic technology and patient-derived cells. This platform enables 3D tissue cultivation and disease-specific microenvironment simulation, providing critical insights into rare skin diseases and supporting the development of targeted treatments.
Your Trusted Partner in Rare Disease Drug Discovery and Development
Specializing in rare diseases, our company offers a comprehensive solution covering all aspects of diagnostic and therapeutic development. Our experienced team, armed with state-of-the-art technology, stands out by delivering customized solutions that address our clients' specific requirements.
Customized Solutions for Hair-Bearing Skin Organoid Model Development
The search for physiologically relevant human skin models is a long-standing challenge in dermatological research and drug discovery. Protheragen is a skin disorders preclinical research service provider dedicated to offering an integrated solution from discovery to safety evaluation. Our company provides hair-bearing skin organoid model development services, which is also a substantial advancement in a robust and relevant in vitro system that recapitulates essential aspects of complex skin physiology to provide for more accurate predictive research.
Customized Solutions for Bronchiolitis Obliterans Syndrome Drug R&D
Bronchiolitis obliterans syndrome (BOS) is a progressive fibrotic lung disease marked by the irreversible obstruction of small airways and most commonly develops as a complication of lung transplantation or chemical exposure. Therapeutics are few, and pathophysiology complex, advancing research demands highly specialized and reliable preclinical models.
Pulmonary Arterial Hypertension (PAH) Animal Model Service
A complex and progressive disorder characterized by profound vasoconstriction and pathological remodeling of the pulmonary arterioles, pulmonary arterial hypertension (PAH) drives sustained elevation in pulmonary vascular resistance, ultimately culminating in right ventricular failure and premature mortality.
Customized Solutions for Food Allergy Animal Model
Affecting a significant and growing portion of the global population, food allergy is a pathological, potentially life-threatening immune response triggered by specific food allergens. For biopharmaceutical companies and research institutions advancing therapeutics into this complex space, the translation from target discovery to success demands physiologically relevant preclinical models.
Customized Solutions for Systemic Sclerosis (SSc) Animal Model Development
Systemic sclerosis (SSc) is a chronic, multisystem autoimmune disorder characterized by progressive fibrosis of the skin and internal organs, vasculopathy, and immune dysregulation. Despite advances in understanding its pathogenesis, limited therapy options exist. Reliable and relevant animal models remain essential for deciphering disease mechanisms and evaluating novel therapeutic candidates.
Customized Solutions for Systemic Lupus Erythematosus (SLE) Model Development
Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disorder characterized by loss of self-tolerance, autoantibody production, immune complex deposition, and heterogeneous manifestations ranging from mild cutaneous involvement to severe renal, neurological, and hematological complications.
Customized Solutions for Ankylosing Spondylitis Model Development
Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease primarily affecting the sacroiliac joints and axial skeleton, often leading to spinal fusion, reduced mobility, and significant functional impairment.
Customized Solutions for Eosinophilic Esophagitis (EoE) Model Development
Eosinophilic esophagitis (EoE) is a chronic, allergen-mediated inflammatory condition of the esophagus, characterized by dense eosinophilic infiltration, esophageal dysfunction, and tissue remodeling.
Preclinical Research Services for PBC and Cholestatic Liver Disease Models
Driven by an autoimmune attack on the intrahepatic bile ducts, primary biliary cholangitis (PBC) is a progressive, immune-mediated cholestatic liver disorder characterized by chronic bile stasis, debilitating hepatic inflammation, and a high risk of progressing to cirrhosis or liver failure.
Customized Solutions for Post-Traumatic Osteoarthritis (PTOA) Model Development
Post‑traumatic osteoarthritis (PTOA) is a degenerative joint disease that arises following a known mechanical insult or traumatic injury to the articular joint. Traumatic destabilizing injuries to the knee, particularly anterior cruciate ligament tears, meniscal tears, and intra‑articular fractures, significantly increase the risk of developing osteoarthritis in middle age.
Customized Solutions for Myeloproliferative Neoplasms (MPNs) Model Development
Characterized by the clonal proliferation of mature myeloid lineages, myeloproliferative neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF), present distinct therapeutic challenges driven by specific somatic mutations such as JAK2 V617F, CALR, and MPL.
Customized Solutions for Nephrectomy Model Development
Chronic kidney disease (CKD) is characterized by progressive renal function loss lasting over three months. As disease progression leads to glomerulosclerosis and tubulointerstitial fibrosis, the 5/6 nephrectomy (remnant kidney) model serves as a gold-standard surgical platform. By resecting ~83% of total renal mass, this model triggers hyperfiltration injury, hemodynamic changes, and progressive functional decline, making it an indispensable tool for mechanistic studies and novel therapy evaluation.
Custom Solutions for Down Syndrome Animal Model Development
Down syndrome (Trisomy 21) is the most common genetic cause of intellectual disability worldwide, caused by the presence of an extra full or partial copy of human chromosome 21. This genetic dosage imbalance affects multiple biological systems, leading to a complex spectrum of clinical manifestations including severe cognitive impairment, early-onset Alzheimer’s disease pathology, congenital heart defects, and metabolic abnormalities. To unravel these multifaceted disease mechanisms and evaluate potential therapeutic interventions, high-fidelity animal models that closely recapitulate human chromosomal alterations and clinical phenotypes are indispensable.
Custom Solutions for Obese Beagle Dog Model Development
Obese animal models serve as critical translational bridges in metabolic disorder research, enabling researchers to investigate the complex pathophysiological mechanisms of human obesity and evaluate novel therapeutic interventions. Large animal models, particularly dogs, closely mirror human organ physiology, metabolic pathways, and body scale, making them indispensably superior to conventional rodent models for translational drug validation and device testing.
Custom Solutions for IgA Nephropathy (IgAN) Animal Model Development
IgA nephropathy (IgAN) is one of the most common primary glomerulonephritides globally and a major driver of progressive kidney failure leading to end-stage renal disease (ESRD). Characterized by complex multi-hit immunopathological mechanisms, the disease presents significant challenges in therapeutic intervention. Preclinical research relies heavily on robust, clinically relevant animal models that mimic human pathophysiology to elucidate underlying mechanisms and evaluate promising therapeutic candidates.
Customized Solutions for Gene-Edited Rabbit & Pig Model Development
Driven by a commitment to bridging the gap between benchtop discovery and translational success, Protheragen’s platform provides end-to-end, customized gene-edited model development, specializing in both Gene-Edited Rabbit Models and Gene-Edited Pig Models, alongside comprehensive preclinical research services. Combining state-of-the-art precision genome editing with high-throughput characterization, our advanced translational capabilities empower global biopharmaceutical partners to accelerate candidate validation.
